qh6ygu1

Property	Value
?:abstract	(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates the respiratory epithelium through angiotensin-converting enzyme-2 (ACE2) binding. Myocardial and endothelial expression of ACE2 could account for the growing body of reported evidence of myocardial injury in severe forms of Human Coronavirus Disease 2019 (COVID-19). We aimed to provide insight into the impact of troponin (hsTnI) elevation on SARS-CoV-2 outcomes in patients hospitalized for COVID-19. (2) Methods: This was a retrospective analysis of hospitalized adult patients with the SARS-CoV-2 infection admitted to a university hospital in France. The observation period ended at hospital discharge. (3) Results: During the study period, 772 adult, symptomatic COVID-19 patients were hospitalized for more than 24 h in our institution, of whom 375 had a hsTnI measurement and were included in this analysis. The median age was 66 (55–74) years, and there were 67% of men. Overall, 205 (55%) patients were placed under mechanical ventilation and 90 (24%) died. A rise in hsTnI was noted in 34% of the cohort, whereas only three patients had acute coronary syndrome (ACS) and one case of myocarditis. Death occurred more frequently in patients with hsTnI elevation (HR 3.95, 95% CI 2.69–5.71). In the multivariate regression model, a rise in hsTnI was independently associated with mortality (OR 3.12, 95% CI 1.49–6.65) as well as age ≥ 65 years old (OR 3.17, 95% CI 1.45–7.18) and CRP ≥ 100 mg/L (OR 3.62, 95% CI 1.12–13.98). After performing a sensitivity analysis for the missing values of hsTnI, troponin elevation remained independently and significantly associated with death (OR 3.84, 95% CI 1.78–8.28). (4) Conclusion: Our study showed a four-fold increased risk of death in the case of a rise in hsTnI, underlining the prognostic value of troponin assessment in the COVID-19 context.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/9qh6ygu1_hasAnnotation_C0020517> <https://research.tib.eu/covid-19/entity/9qh6ygu1_hasAnnotation_C0746730> <https://research.tib.eu/covid-19/entity/9qh6ygu1_hasAnnotation_C1417645> <https://research.tib.eu/covid-19/entity/9qh6ygu1_hasAnnotation_C1417647> <https://research.tib.eu/covid-19/entity/9qh6ygu1_hasAnnotation_C1825598> <https://research.tib.eu/covid-19/entity/9qh6ygu1_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Cordeanu%2C_Elena-Mihaela%3B_Duthil%2C_Nicolas%3B_Severac%2C_Francois%3B_Lambach%2C_H%C3%A9l%C3%A8ne%3B_Tousch%2C_Jonathan%3B_Jambert%2C_Lucas%3B_Mirea%2C_Corina%3B_Delatte%2C_Alexandre%3B_Younes%2C_Wa%C3%ABl%3B_Frantz%2C_Anne-Sophie%3B_Merdji%2C_Hamid%3B_Schini-Kerth%2C_Val%C3%A9rie%3B_Bilbault%2C_Pascal%3B_Ohlmann%2C_Patrick%3B_Andres%2C_Emmanuel%3B_Stephan%2C_Dominique>
?:doi	<https://research.tib.eu/covid-19/entity/10.3390/jcm9124078>
?:doi	10.3390/jcm9124078
?:journal	J_Clin_Med
?:license	cc-by
?:pdf_json_files	document_parses/pdf_json/fc12bc1e52afe56e7c23b990abbbb8b4c4beb089.json
?:pmc_json_files	document_parses/pmc_json/PMC7766903.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7766903>
?:pmid	<https://research.tib.eu/covid-19/entity/33348719.0>
?:pmid	33348719.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/fc12bc1e52afe56e7c23b990abbbb8b4c4beb089>
?:source	Medline; PMC
?:title	Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-17

Property

Value

?:abstract

(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates the respiratory epithelium through angiotensin-converting enzyme-2 (ACE2) binding. Myocardial and endothelial expression of ACE2 could account for the growing body of reported evidence of myocardial injury in severe forms of Human Coronavirus Disease 2019 (COVID-19). We aimed to provide insight into the impact of troponin (hsTnI) elevation on SARS-CoV-2 outcomes in patients hospitalized for COVID-19. (2) Methods: This was a retrospective analysis of hospitalized adult patients with the SARS-CoV-2 infection admitted to a university hospital in France. The observation period ended at hospital discharge. (3) Results: During the study period, 772 adult, symptomatic COVID-19 patients were hospitalized for more than 24 h in our institution, of whom 375 had a hsTnI measurement and were included in this analysis. The median age was 66 (55–74) years, and there were 67% of men. Overall, 205 (55%) patients were placed under mechanical ventilation and 90 (24%) died. A rise in hsTnI was noted in 34% of the cohort, whereas only three patients had acute coronary syndrome (ACS) and one case of myocarditis. Death occurred more frequently in patients with hsTnI elevation (HR 3.95, 95% CI 2.69–5.71). In the multivariate regression model, a rise in hsTnI was independently associated with mortality (OR 3.12, 95% CI 1.49–6.65) as well as age ≥ 65 years old (OR 3.17, 95% CI 1.45–7.18) and CRP ≥ 100 mg/L (OR 3.62, 95% CI 1.12–13.98). After performing a sensitivity analysis for the missing values of hsTnI, troponin elevation remained independently and significantly associated with death (OR 3.84, 95% CI 1.78–8.28). (4) Conclusion: Our study showed a four-fold increased risk of death in the case of a rise in hsTnI, underlining the prognostic value of troponin assessment in the COVID-19 context.

is ?:annotates of